Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1980 Sep;18(3):386–389. doi: 10.1128/aac.18.3.386

Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function.

M Ohkawa, M Orito, T Sugata, M Shimamura, M Sawaki, E Nakashita, K Kuroda, K Sasahara
PMCID: PMC284011  PMID: 6932824

Abstract

The pharmacokinetics of cefmetazole, a new cephamycin antibiotic, were examined after a 1-h intravenous drip infusion of 1 g to 5 healthy volunteers with normal renal function and 16 patients with impaired renal function. Peak serum concentrations were obtained at the end of the infusion in all subjects, regardless of their renal function. Approximately 70% of the infused dose was excreted in the urine within 6 h in healthy volunteers. The pharmacokinetic parameters of cefmetazole were derived by analyzing elimination data, with a one-compartment open model. The mean serum half-life of cefmetazole in healthy volunteers was 0.81 h. A significant correlation between the elimination rate constant and the creatinine clearance was demonstrated.

Full text

PDF
386

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brumfitt W., Kosmidis J., Hamilton-Miller J. M., Gilchrist J. N. Cefoxitin and cephalothin: antimicrobial activity, human pharmacokinetics, and toxicology. Antimicrob Agents Chemother. 1974 Sep;6(3):290–299. doi: 10.1128/aac.6.3.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Craig W. A., Welling P. G., Jackson T. C., Kunin C. M. Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency. J Infect Dis. 1973 Oct;128(Suppl):S347–S345. doi: 10.1093/infdis/128.supplement_2.s347. [DOI] [PubMed] [Google Scholar]
  3. Fillastre J. P., Leroy A., Godin M., Oksenhendler G., Humbert G. Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients. J Antimicrob Chemother. 1978 Jul;4(B):79–83. doi: 10.1093/jac/4.suppl_b.79. [DOI] [PubMed] [Google Scholar]
  4. Goodwin C. S., Raftery E. B., Goldberg A. D., Skeggs H., Till A. E., Martin C. M. Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. Antimicrob Agents Chemother. 1974 Sep;6(3):338–346. doi: 10.1128/aac.6.3.338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kirby W. M., Regamey C. Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis. 1973 Oct;128(Suppl):S341–S346. doi: 10.1093/infdis/128.supplement_2.s341. [DOI] [PubMed] [Google Scholar]
  6. Kunin C. M. A guide to use of antibiotics in patients with renal disease. A table of recommended doses and factors governing serum levels. Ann Intern Med. 1967 Jul;67(1):151–158. doi: 10.7326/0003-4819-67-1-151. [DOI] [PubMed] [Google Scholar]
  7. Levison M. E., Levison S. P., Ries K., Kaye D. Pharmacology of cefazolin in patients with normal and abnormal renal function. J Infect Dis. 1973 Oct;128(Suppl):S354–S357. doi: 10.1093/infdis/128.supplement_2.s354. [DOI] [PubMed] [Google Scholar]
  8. Miller A. K., Celozzi E., Kong Y., Pelak B. A., Kropp H., Stapley E. O., Hendlin D. Cephamycins, a new family of beta-lactam antibiotics. IV. In vivo studies. Antimicrob Agents Chemother. 1972 Oct;2(4):287–290. doi: 10.1128/aac.2.4.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Nakao H., Yanagisawa H., Shimizu B., Kaneko M., Nagano M. A new semisynthetic 7alpha-methoxycephalosporin, CS-1170: 7beta-((cyanomethyl)thio)acetamido)-7alpha-methoxy-3-((1-methyl-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid. J Antibiot (Tokyo) 1976 May;29(5):554–558. doi: 10.7164/antibiotics.29.554. [DOI] [PubMed] [Google Scholar]
  10. Schrogie J. J., Davies R. O., Yeh K. C., Rogers D., Holmes G. I., Skeggs H., Martin C. M. Bioavailability and pharmacokinetics of cefoxitin sodium. J Antimicrob Chemother. 1978 Jul;4(B):69–78. doi: 10.1093/jac/4.suppl_b.69. [DOI] [PubMed] [Google Scholar]
  11. Sonneville P. F., Kartodirdjo R. R., Skeggs H., Till A. E., Martin C. M. Comparative clinical pharmacology of intravenous cefoxitin and cephalothin. Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):397–403. doi: 10.1007/BF00606555. [DOI] [PubMed] [Google Scholar]
  12. Wallick H., Hendlin D. Cefoxitin, a semisynthetic cephamycin antibiotic: susceptibility studies. Antimicrob Agents Chemother. 1974 Jan;5(1):25–32. doi: 10.1128/aac.5.1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES